DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Circulating Tumor Cell, Cell Free DNA, Exosome and Vesicle Cancer Diagnostic Markets 2016-2020" report to their offering.
A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.
Use independent research that makes you the expert. Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly.
The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers. What is the size of the huge screening opportunity?
Companies Mentioned Include:
- AdnaGen (now Qiagen)
- Bio-Rad Laboratories
- Boreal Genomics
- Cytolumina Technologies Corp
- Diagnologix LLC
- Epic Sciences
- Exosome Diagnostics
- Fluidigm Corp
- HTG Molecular Diagnostics
- Janssen Diagnostics
- Liquid Biotech USA, Inc.
- RainDance Technologies
- SRI International
- Sysmex Corporation
- Sysmex Inostics
1. Introduction and Market Definition
2. Market Overview
3. Market Trends
4. Liquid Biopsy Recent Developments
5. Country Market Sizes - North America
6. Country Markets - Europe
7. Country Markets - Asia Pacific
8. Country Markets - Latin America, Africa & The Middle East
9. Global Market Summary
10. Potential Market Opportunity Sizes
For more information visit http://www.researchandmarkets.com/research/542cbh/circulating_tumor